Additionally, treatment of HBAAV‐TBG‐shALKBH5 or/and CCR6 inhibitor markedly decreased tumour volume and liver/body weight ratio, promoted tumour necrosis and inhibited ALKBH5/TIRAP axis in tumour (Figure 6D,E,G). Here, CCR6 is linked to neoplasm.